Biocept to Present at the Proactive One2One Virtual Investor Forum on August 25
August 20 2020 - 8:30AM
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
liquid biopsy tests designed to provide physicians with clinically
actionable information to improve the outcomes of patients,
announces that President and CEO Michael Nall will present at the
Proactive One2One Virtual Investor Forum, North America on Tuesday,
August 25 at 1:00 p.m. Eastern time (10 a.m. Pacific time).
The virtual event will include a brief company overview followed
by a fully interactive Q&A session. The live event can be
accessed here and will be archived on the Investor Relations
section of the Biocept website.
About Biocept Biocept, Inc. is a molecular
diagnostics company with commercialized assays for lung, breast,
gastric, colorectal and prostate cancers, and melanoma. The Company
uses its proprietary liquid biopsy technology to provide physicians
with clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. In
addition, Biocept recently added COVID-19 testing to
support efforts to fight the pandemic. For additional information,
please visit www.biocept.com.
Investor Contact: LHA
Investor Relations Jody
CainJcain@lhai.com 310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024